FI4037685T3 - Serca:a moduloiva kinoliini ja sen käyttö sairauden hoidossa - Google Patents
Serca:a moduloiva kinoliini ja sen käyttö sairauden hoidossa Download PDFInfo
- Publication number
- FI4037685T3 FI4037685T3 FIEP21845832.1T FI21845832T FI4037685T3 FI 4037685 T3 FI4037685 T3 FI 4037685T3 FI 21845832 T FI21845832 T FI 21845832T FI 4037685 T3 FI4037685 T3 FI 4037685T3
- Authority
- FI
- Finland
- Prior art keywords
- medicinal composition
- serca
- quinoline
- modulate
- treating disease
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 claims 6
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/40—Nitrogen atoms attached in position 8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/932,832 US20200347038A1 (en) | 2014-08-29 | 2020-07-20 | Quinolines that modulate serca and their use for treating disease |
| PCT/US2021/042235 WO2022020261A1 (en) | 2020-07-20 | 2021-07-19 | Quinolines that modulate serca and their use for treating disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4037685T3 true FI4037685T3 (fi) | 2023-11-27 |
Family
ID=79729478
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP21845832.1T FI4037685T3 (fi) | 2020-07-20 | 2021-07-19 | Serca:a moduloiva kinoliini ja sen käyttö sairauden hoidossa |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP4037685B9 (enExample) |
| JP (1) | JP7705445B2 (enExample) |
| CN (1) | CN116744928A (enExample) |
| CA (1) | CA3186668A1 (enExample) |
| DK (1) | DK4037685T3 (enExample) |
| ES (1) | ES2968041T3 (enExample) |
| FI (1) | FI4037685T3 (enExample) |
| HU (1) | HUE064550T2 (enExample) |
| PL (1) | PL4037685T3 (enExample) |
| PT (1) | PT4037685T (enExample) |
| WO (1) | WO2022020261A1 (enExample) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101784533B (zh) * | 2007-08-22 | 2013-08-21 | 艾博特股份有限两合公司 | 4-苄基氨基喹啉、含有它们的药物组合物和它们在治疗中的用途 |
| CN104302640A (zh) * | 2012-03-16 | 2015-01-21 | 埃克希金医药品有限公司 | 3,5-二氨基吡唑激酶抑制剂 |
| US10772881B2 (en) * | 2017-02-27 | 2020-09-15 | Russell Dahl | Quinolines that modulate SERCA and their use for treating disease |
| US20170281611A1 (en) * | 2014-08-29 | 2017-10-05 | Eiger Biopharmaceuticals, Inc. | Quinolines and their use for treating endoplasmic reticulum stress-caused diseases |
| US20200347038A1 (en) * | 2014-08-29 | 2020-11-05 | Russell Dahl | Quinolines that modulate serca and their use for treating disease |
| CN106966973A (zh) * | 2017-05-18 | 2017-07-21 | 湖北工业大学 | N‑苯基‑n‑（2‑甲基‑8‑喹啉基）苯甲酰胺的制备方法 |
-
2021
- 2021-07-19 CA CA3186668A patent/CA3186668A1/en active Pending
- 2021-07-19 CN CN202180063849.1A patent/CN116744928A/zh active Pending
- 2021-07-19 PT PT218458321T patent/PT4037685T/pt unknown
- 2021-07-19 PL PL21845832.1T patent/PL4037685T3/pl unknown
- 2021-07-19 EP EP21845832.1A patent/EP4037685B9/en active Active
- 2021-07-19 DK DK21845832.1T patent/DK4037685T3/da active
- 2021-07-19 JP JP2023504102A patent/JP7705445B2/ja active Active
- 2021-07-19 ES ES21845832T patent/ES2968041T3/es active Active
- 2021-07-19 WO PCT/US2021/042235 patent/WO2022020261A1/en not_active Ceased
- 2021-07-19 HU HUE21845832A patent/HUE064550T2/hu unknown
- 2021-07-19 FI FIEP21845832.1T patent/FI4037685T3/fi active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022020261A1 (en) | 2022-01-27 |
| JP7705445B2 (ja) | 2025-07-09 |
| EP4037685A4 (en) | 2022-11-30 |
| DK4037685T3 (en) | 2024-01-02 |
| EP4037685B1 (en) | 2023-09-20 |
| WO2022020261A9 (en) | 2022-09-09 |
| CA3186668A1 (en) | 2022-01-27 |
| ES2968041T3 (es) | 2024-05-06 |
| CN116744928A (zh) | 2023-09-12 |
| PT4037685T (pt) | 2023-12-28 |
| HUE064550T2 (hu) | 2024-03-28 |
| EP4037685B9 (en) | 2024-03-06 |
| PL4037685T3 (pl) | 2024-04-02 |
| JP2023534992A (ja) | 2023-08-15 |
| EP4037685A1 (en) | 2022-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ777871A (en) | Small molecule modulators of il-17 | |
| EP4563150A3 (en) | New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer | |
| WO2021147236A9 (zh) | 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用 | |
| EP4344743A3 (en) | Heterocyclic flavone derivatives, compositions, and methods related thereto | |
| UA92181C2 (ru) | Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера | |
| JP2009500443A5 (enExample) | ||
| PH12017501421B1 (en) | Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n`-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine | |
| FI3681857T3 (fi) | Fluorifenyyli-beeta-hydroksietyyliamiineja ja niiden käyttö hyperglykaemian hoidossa | |
| NZ630589A (en) | Methods of treating alzheimer’s disease and pharmaceutical compositions thereof | |
| SE0104340D0 (sv) | New compounds | |
| MX2022015554A (es) | Moduladores de molecula peque?a de interleucina 17 (il-17). | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| UA117506C2 (uk) | Фармацевтичний препарат, який містить сполуку піридиламінооцтової кислоти | |
| WO2017182873A3 (en) | Peptide-oligourea foldamer compounds and methods of their use | |
| JP2022531251A5 (enExample) | ||
| JOP20240055A1 (ar) | عقار أولي من مشتقات بيروليدون كمنشط جلوكوكيناز | |
| MY189740A (en) | Butylphthalide-telmisartan heterocomplex, preparation method and application thereof | |
| MX2024014315A (es) | Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas | |
| ZA202309001B (en) | Abhd6 antagonist | |
| MX2023012521A (es) | Formas en estado solido de (s)-n-(3-(2-((r)-1-hidroxipropano-2-il) amino)-6-morfolinopiridin-4-il)-4-metilfenil)-3-(2,2,2-trifluoroe til)pirrolidin-1-carboxamida y sales de las mismas. | |
| WO2024100452A3 (en) | Heterocyclic compounds as sting agonists | |
| GB2590189A9 (en) | Lycorine derivatives, pharmaceutical composite thereof and usage therefor | |
| MX2026000979A (es) | Una forma farmaceutica solida de dosificacion bucodispersable de safinamida | |
| MX2025010948A (es) | Derivados fusionados con tiofeno sustituido, composiciones que los comprenden y su uso como productos farmacéuticos |